Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 20 peer-reviewed journal articles Updated
Oncology

Treatment Strategy: Balancing Your Graft and Your Recovery

At a Glance

Treating PTLD requires a careful balance to protect your transplanted organ while stopping abnormal cell growth. The main steps usually include reducing anti-rejection medications (RIS), followed by targeted therapies like Rituximab, or chemotherapy if the disease is more aggressive.

Treating PTLD requires a delicate “balancing act.” Your doctors must find the sweet spot between two opposing goals: weakening the immune system enough to keep your transplanted organ safe, but strengthening it enough to fight off the PTLD [1][2].

The Multi-Team Approach

Because PTLD involves both your transplant and a cancer-like growth, you must have two teams working in lockstep:

  • The Transplant Team: Experts in protecting your graft (the new organ or cells).
  • The Oncology/Hematology Team: Experts in treating lymphoproliferative disorders.
    Close communication between these teams is essential to ensure that a treatment for one condition doesn’t accidentally destroy the other [3][1].

Step 1: Reduction of Immunosuppression (RIS)

For many PTLD patients, the first line of defense is Reduction of Immunosuppression (RIS) [4].

  • The Rationale: By lowering the dose of your anti-rejection drugs, your own immune system (specifically your T-cells) can “wake up” and begin to recognize and attack the abnormal B-cells [4][5].
  • The Timeline: Doctors typically trial RIS for 2 to 4 weeks. During this scary ‘wait and see’ period, your team will monitor you closely with blood tests or scans before deciding if they need to escalate treatment [6][7].
  • The Exception: If you have an aggressive subtype, like monomorphic PTLD, your doctors may skip RIS or move immediately to combining it with chemotherapy so they do not waste time [8][9].
  • The Risk: The main danger of RIS is graft rejection. Your transplant team will monitor you closely for signs that your body is starting to attack the new organ [6][10].

Step 2: Targeted Therapy (Rituximab)

If RIS alone isn’t enough, or if the PTLD is more advanced, doctors often add Rituximab [10].

  • How it works: Rituximab is a monoclonal antibody that targets a protein called CD20 found on the surface of most B-cells [8].
  • Safety Considerations: While it does not typically increase the risk of organ rejection, Rituximab carries risks of severe infusion reactions. It can also cause other dormant viruses (like Hepatitis B) to reactivate, so your doctor will require viral screening before you start [6][11].

Step 3: Chemotherapy (R-CHOP)

For aggressive cases, doctors may move to combination chemotherapy, such as R-CHOP (a powerful combination of five specific chemotherapy drugs: Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) [9][12].

  • The Strategy: Often, doctors use a sequential approach: they start with Rituximab and then add R-CHOP if the tumor doesn’t fully disappear [8][9].
  • Safety Warning: Chemotherapy severely weakens your already compromised immune system. You will be at extreme risk for infections. If you develop a fever during chemotherapy, it is a medical emergency (neutropenic fever) and you must seek immediate care [13].
  • Note for Parents: While the overall steps are similar, pediatric patients may receive different specific chemotherapy combinations or dosages tailored to their developing bodies [14].

Infection Prophylaxis

Because treatments like Rituximab and chemotherapy further weaken your immune system, doctors will almost certainly prescribe additional prophylactic (preventative) medications. Expect to take special antibiotics, antivirals, or antifungals to protect you from opportunistic infections during your treatment [4].

Advanced Options: Cellular Therapies

For PTLD that is EBV-positive and does not respond to standard treatments (refractory), specialized cellular therapies are becoming a vital option [15][16].

  • EBV-Specific T-Cells (EBV-CTLs): These are T-cells that have been “trained” in a lab to specifically find and kill cells infected with EBV [15][17].
  • Tabelecleucel: This is a leading “off-the-shelf” T-cell therapy that has shown success in treating refractory EBV-positive PTLD [15][18].
  • Note: These highly specialized therapies may only be available at major academic transplant and cancer centers, or through clinical trials.

Managing the Risk of Rejection

Throughout your treatment, your transplant team will use blood tests (like creatinine for kidneys or liver enzymes) and sometimes biopsies to watch for rejection [19][20]. Interestingly, research suggests that if a rejection episode does occur during PTLD treatment, it often does not negatively impact long-term survival, provided it is managed carefully by your multidisciplinary team [6].

Common questions in this guide

What is the first step in treating PTLD?
For many patients, the first step is Reduction of Immunosuppression (RIS). By lowering your anti-rejection medications, your immune system can wake up and naturally begin to attack the abnormal PTLD cells.
Will treating PTLD cause my transplanted organ to be rejected?
There is a risk of graft rejection when reducing immunosuppression medications. Your transplant team will monitor your organ function closely using blood tests to catch and manage any signs of rejection early.
What happens if lowering my anti-rejection drugs doesn't work for PTLD?
If reducing medications isn't enough or if your PTLD is advanced, doctors often add targeted therapies like Rituximab. In more aggressive cases, combination chemotherapy like R-CHOP may also be necessary.
What is tabelecleucel used for in PTLD?
Tabelecleucel is a specialized cellular therapy used for PTLD that is driven by the Epstein-Barr virus (EBV) and has not responded to standard treatments. It uses specially trained T-cells to find and destroy EBV-infected cells.
Why do I need to take preventative antibiotics during PTLD treatment?
Treatments like Rituximab and chemotherapy severely weaken your immune system. You must take prophylactic medications, such as specific antibiotics or antivirals, to prevent dangerous opportunistic infections during your care.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.How will you coordinate my care between the transplant team and the oncology team? Who is the main point of contact?
  2. 2.Given my specific subtype (e.g., monomorphic), are we starting with only Reduction of Immunosuppression (RIS), or do we need to start Rituximab or chemotherapy right away?
  3. 3.What is our backup plan if the initial reduction in my medications doesn't shrink the tumor within a few weeks?
  4. 4.How will we monitor my organ function during this time to catch signs of rejection as early as possible?
  5. 5.If my PTLD is EBV-positive, at what point would we consider specialized T-cell therapies like tabelecleucel?
  6. 6.What specific prophylactic medications will I be taking to prevent infections during my treatment?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (20)
  1. 1

    Successful Treatment of Ocular Post-Transplant Lymphoproliferative Disorder with Obinutuzumab in an 8-Year-Old Boy Following Kidney Transplant: A Case Report.

    Lussier C, Larche CL, Vadboncoeur J

    Ocular immunology and inflammation 2025; (33(7)):1483-1488 doi:10.1080/09273948.2025.2495070.

    PMID: 40255019
  2. 2

    Incidence and mortality of post-transplant lymphoproliferative disorders after kidney transplantation: A real-world retrospective analysis in Japan.

    Kato T, Yoshida T, Taniguchi A, et al.

    International journal of urology : official journal of the Japanese Urological Association 2022; (29(3)):206-211 doi:10.1111/iju.14750.

    PMID: 34897833
  3. 3

    Management of Diffuse Large B-Cell Lymphoma as Post-Transplant Lymphoproliferative Disorder in a Kidney Transplant Recipient: A Case Report.

    Alshemmari S, Hamadah A, Ousia S, et al.

    Hematology reports 2025; (17(3)) doi:10.3390/hematolrep17030022.

    PMID: 40407632
  4. 4

    Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.

    Allen UD, Preiksaitis JK,

    Clinical transplantation 2019; (33(9)):e13652 doi:10.1111/ctr.13652.

    PMID: 31230381
  5. 5

    Post-transplant lymphoproliferative disorders.

    Dharnidharka VR, Webster AC, Martinez OM, et al.

    Nature reviews. Disease primers 2016; (2()):15088 doi:10.1038/nrdp.2015.88.

    PMID: 27189056
  6. 6

    Reduction of immunosuppression for post-transplant lymphoproliferative disorder (PTLD): a single-center experience of allograft survival outcomes.

    Pan K, Franke AJ, Skelton WP, et al.

    Leukemia & lymphoma 2021; (62(5)):1123-1128 doi:10.1080/10428194.2020.1861266.

    PMID: 33327817
  7. 7

    Epstein-Barr virus-positive post-transplant lymphoproliferative disordepresenting as hematochezia and enterobrosis in renal transplant recipients in China: A report of two cases.

    Sun ZJ, Hu XP, Fan BH, Wang W

    World journal of clinical cases 2019; (7(24)):4334-4341 doi:10.12998/wjcc.v7.i24.4334.

    PMID: 31911916
  8. 8

    Modified risk-stratified sequential treatment (subcutaneous rituximab with or without chemotherapy) in B-cell Post-transplant lymphoproliferative disorder (PTLD) after Solid organ transplantation (SOT): the prospective multicentre phase II PTLD-2 trial.

    Zimmermann H, Koenecke C, Dreyling MH, et al.

    Leukemia 2022; (36(10)):2468-2478 doi:10.1038/s41375-022-01667-1.

    PMID: 35974101
  9. 9

    Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial.

    Trappe RU, Dierickx D, Zimmermann H, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017; (35(5)):536-543 doi:10.1200/JCO.2016.69.3564.

    PMID: 27992268
  10. 10

    Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines.

    Styczynski J, van der Velden W, Fox CP, et al.

    Haematologica 2016; (101(7)):803-11 doi:10.3324/haematol.2016.144428.

    PMID: 27365460
  11. 11

    Management of post-transplant lymphoproliferative disorders.

    Llaurador G, McLaughlin L, Wistinghausen B

    Current opinion in pediatrics 2017; (29(1)):34-40 doi:10.1097/MOP.0000000000000445.

    PMID: 27906865
  12. 12

    Diverse clinical and histopathologic features of cutaneous post-transplant lymphoproliferative disorders: A presentation of two cases.

    Roberts SJ, McNally B, Rosser JA, et al.

    The Australasian journal of dermatology 2019; (60(4)):e317-e321 doi:10.1111/ajd.13076.

    PMID: 31144292
  13. 13

    Relationship of Post-Transplant Lymphoproliferative Disorders (PTLD) Subtypes and Clinical Outcome in Pediatric Heart Transplant Recipients: A Retrospective Single Institutional Analysis/Experience of 558 Patients.

    Liu Y, Wang BC, Zuppan CW, et al.

    Cancers 2023; (15(3)) doi:10.3390/cancers15030976.

    PMID: 36765933
  14. 14

    Impact of antiviral prophylaxis on EBV viremia and posttransplant lymphoproliferative disorders in solid organ transplant recipients: a systematic review and meta-analysis.

    Moghadamnia M, Delroba K, Heidari S, et al.

    Virology journal 2025; (22(1)):11 doi:10.1186/s12985-025-02623-y.

    PMID: 39815274
  15. 15

    Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial.

    Mahadeo KM, Baiocchi R, Beitinjaneh A, et al.

    The Lancet. Oncology 2024; (25(3)):376-387 doi:10.1016/S1470-2045(23)00649-6.

    PMID: 38309282
  16. 16

    Comparative analysis of tabelecleucel and current treatment in patients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease following hematopoietic cell transplant or solid organ transplant.

    Barlev A, Zimmermann H, Guzman-Becerra N, et al.

    Journal of medical economics 2024; (27(1)):789-795 doi:10.1080/13696998.2024.2354150.

    PMID: 38727527
  17. 17

    Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation.

    Prockop S, Doubrovina E, Suser S, et al.

    The Journal of clinical investigation 2020; (130(2)):733-747.

    PMID: 31689242
  18. 18

    Tabelecleucel for EBV+ PTLD after allogeneic HCT or SOT in a multicenter expanded access protocol.

    Nikiforow S, Whangbo JS, Reshef R, et al.

    Blood advances 2024; (8(12)):3001-3012 doi:10.1182/bloodadvances.2023011626.

    PMID: 38625984
  19. 19

    Intussusception Can Be the First Sign of Post-transplant Lymphoproliferative Disease.

    Atici SD, Arican C, Avci EK, et al.

    Transplantation proceedings 2019; (51(4)):1184-1186 doi:10.1016/j.transproceed.2019.01.085.

    PMID: 31101196
  20. 20

    [Primary central nervous system post-transplant lymphoproliferative disorder with few specific abnormal findings observed on MRI and in the cerebrospinal fluid].

    Takeuchi Y, Ochiai J, Onoda O, et al.

    Rinsho shinkeigaku = Clinical neurology 2022; (62(1)):44-48 doi:10.5692/clinicalneurol.cn-001677.

    PMID: 34924473

This page provides educational information about PTLD treatments. Always consult your transplant and oncology teams to determine the safest treatment plan for your specific case and to monitor your organ function.

Get notified when new evidence is published on Post-transplant lymphoproliferative disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.